Global Immuno-Oncology Cell Therapy Market Size is valued at USD 11.9 Billion in 2024 and is predicted to reach USD 95.3 Billion by the year 2034 at a 23.2% CAGR during the forecast period for 2025-2034.
Immuno-oncology cell therapies are a remarkably promising treatment for a different types of cancer patients. The approval of CAR-T cell therapy products represents one of the most significant breakthroughs in cancer since the introduction of chemotherapy. Immuno-oncology cell therapies are one of the fastest advancing technology along with huge research and development activities. The oncology market today could be quickly superseded by next generation therapies in the upcoming forecast period. The Immuno-oncology Cell Therapy market is driven by factors such as increasing research funding in the immune-oncology, rising prevalence of cancer and focus on research activities from government health institutions and pharma giants inImmuno-oncology therapy development.
The global immuno-oncology cell therapies market is classified based on therapy type and region. Based on the therapy type, the market is segmented into CAR-T Cells, NK & NKT Cells, TAA/TSA targeted T Cell, TCR T Cell, and Other Cell Therapies.Geographically, the Americas dominate the immuno-oncology cell therapies market owing to high healthcare expenditure and the rise in awareness among people. Europe stands for the second position in the immuno-oncology cell therapies market. It is expected that the support provided by government bodies for research & development and increased clinical trial programs in healthcare is going to drive the market in the Europe region. The Asia Pacific is known to be the fastest-growing immuno-oncology cell therapies market leading to a huge patient pool, developing healthcare technology and improving healthcare expenditure. The Middle East & Africa has the lowest market for immuno-oncology cell therapies due to inadequate medical facilities and lack of technical knowledge.
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 11.93 Billion |
| Revenue Forecast In 2034 | USD 95.3 Billion |
| Growth Rate CAGR | CAGR of 23.2% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Mn,and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Therapy Type, By Indication Type, By Cell Source |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
| Competitive Landscape | Novartis, Juno Therapeutics, Agios Pharmaceutical, Atara Biotherapeutics, Shenzhen BinDeBio Ltd., China Immunotech Co., Ltd., Autolus Limited, Kite Pharma, Bellicum Pharmaceuticals, bluebird bio, Calibr, Carina Biotech, CARsgen Therapeutics, Celgene Corporation, Cellectis, Cell Medica, Editas Medicine, Allogene Therapeutics, Amgen, Cell Design Labs, Celularity, Celyad, Fate Therapeutics, Fortress Bio, Gilead Sciences, Sorrento Therapeutics, Inc., Ziopharm, JW Therapeutics, Medigene, MedisixTherapeutics, Lion TCR, Mustang Bio, Nanjing Legend Biotech, Precision Biosciences, Posedia Therapeutics, Zelluna Immunotherapy, and others |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Immuno-oncology Cell Therapy Market Snapshot
Chapter 4. Global Immuno-oncology Cell Therapy Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis of Key Immuno-oncology Cell Therapy Industry
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Clinical Trial/Pipeline Analysis 2021
4.8. COVID-19 Impact on Oncology Industry
Chapter 5. Market Segmentation 1: Therapy Type Estimates & Trend Analysis
5.1. Therapy Type & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Therapy Type:
5.2.1. CAR-T Cells
5.2.2. NK & NKT Cells
5.2.3. TCR T Cells
5.2.4. TAA/TSA targeted T Cell
5.2.5. Cytokine-induced killer cells
5.2.6. Dendritic cells
5.2.7. Macrophages
5.2.8. Other Cell Therapies
Chapter 6. Market Segmentation 2: Indication Type Estimates & Trend Analysis
6.1. Indication Type & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Indication Type:
6.2.1. Head & Neck Cancer
6.2.2. Lung Cancer
6.2.3. Kidney Cancer
6.2.4. Melanoma
6.2.5. Lymphoma
6.2.6. Leukemia
6.2.7. Others
Chapter 7. Immuno-oncology Cell Therapy Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Immuno-oncology Cell Therapy Market revenue (US$ Million) estimates and forecasts by Therapy Type, 2021-2034
7.1.2. North America Immuno-oncology Cell Therapy Market revenue (US$ Million) estimates and forecasts by Indication Type, 2021-2034
7.1.3. North America Immuno-oncology Cell Therapy Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
7.1.3.1. U.S.
7.1.3.2. Canada
7.2. Europe
7.2.1. Europe Immuno-oncology Cell Therapy Market revenue (US$ Million) by Therapy Type, 2021-2034
7.2.2. Europe Immuno-oncology Cell Therapy Market revenue (US$ Million) estimates and forecasts by Indication Type, 2021-2034
7.2.3. Europe Immuno-oncology Cell Therapy Market revenue (US$ Million) by country, 2021-2034
7.2.3.1. Germany
7.2.3.2. Poland
7.2.3.3. France
7.2.3.4. Italy
7.2.3.5. Spain
7.2.3.6. UK
7.2.3.7. Rest of Europe
7.3. Asia Pacific
7.3.1. Asia Pacific Immuno-oncology Cell Therapy Market revenue (US$ Million) by Therapy Type, 2021-2034
7.3.2. Asia Pacific Immuno-oncology Cell Therapy Market revenue (US$ Million) estimates and forecasts by Indication Type, 2021-2034
7.3.3. Asia Pacific Immuno-oncology Cell Therapy Market revenue (US$ Million) by country, 2021-2034
7.3.3.1. China
7.3.3.2. India
7.3.3.3. Japan
7.3.3.4. Australia
7.3.3.5. Rest of Asia Pacific
7.4. Latin America
7.4.1. Latin America Immuno-oncology Cell Therapy Market revenue (US$ Million) by Therapy Type, 2021-2034
7.4.2. Latin America Immuno-oncology Cell Therapy Market revenue (US$ Million) estimates and forecasts by Indication Type, 2021-2034
7.4.3. Latin America Immuno-oncology Cell Therapy Market revenue (US$ Million) by country, (US$ Million) 2021-2034
7.4.3.1. Brazil
7.4.3.2. Rest of Latin America
7.5. Middle East & Africa
7.5.1. Middle East & Africa Immuno-oncology Cell Therapy Market revenue (US$ Million) by Therapy Type, (US$ Million)
7.5.2. Middle East & Africa Immuno-oncology Cell Therapy Market revenue (US$ Million) estimates and forecasts by Indication Type, 2021-2034
7.5.3. Middle East & Africa Immuno-oncology Cell Therapy Market revenue (US$ Million) by country, (US$ Million) 2021-2034
7.5.3.1. South Africa
7.5.3.2. GCC Countries
7.5.3.3. Rest of MEA
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Novartis
8.2.2. Juno Therapeutics
8.2.3. Agios Pharmaceutical
8.2.4. Adicet Bio, Inc.
8.2.5. Adaptimmune Therapeutics plc.
8.2.6. Atara Biotherapeutics
8.2.7. Artiva Biotherapeutics, Inc.
8.2.8. Shenzhen BinDeBio Ltd.
8.2.9. Editas Medicine
8.2.10. China Immunotech Co., Ltd.
8.2.11. CRISPR Therapeutics
8.2.12. Lion TCR
8.2.13. Autolus Limited
8.2.14. Kite Pharma
8.2.15. Bellicum Pharmaceuticals
8.2.16. bluebird bio
8.2.17. Calibr
8.2.18. Carina Biotech
8.2.19. CARsgen Therapeutics
8.2.20. Celgene Corporation
8.2.21. Cellectis
8.2.22. Cell Medica
8.2.23. Allogene Therapeutics
8.2.24. Amgen
8.2.25. Cell Design Labs
8.2.26. Celularity
8.2.27. Celyad
8.2.28. Eureka Therapeutics
8.2.29. Fate Therapeutics
8.2.30. Fortress Bio
8.2.31. Gilead Sciences
8.2.32. Immatics US Inc.
8.2.33. Immunocore
8.2.34. Sorrento Therapeutics, Inc.
8.2.35. Janssen Biotech
8.2.36. JW Therapeutics
8.2.37. Kleo Pharmaceuticals
8.2.38. Medisix Therapeutics
8.2.39. Mustang Bio
8.2.40. Medigene
8.2.41. NantKwest
8.2.42. Nanjing Legend Biotech
8.2.43. Precision Biosciences
8.2.44. Posedia Therapeutics
8.2.45. T-Cure Biosciences Inc
8.2.46. TCR2 Therapeutics
8.2.47. T-knife
8.2.48. TScan Therapeutics
8.2.49. Triumvira Immunologics USA, Inc.
8.2.50. Ziopharm
8.2.51. Zelluna Immunotherapy
8.2.52. 3T Biosciences, Inc.
8.2.53. Other Prominent Players
Global Immuno-oncology Cell Therapy Market Outlook 2021-2034 by Therapy Type
Global Immuno-oncology Cell Therapy Market Outlook 2021-2034 by Major Indication
By Cell Source
Global Immuno-oncology Cell Therapy Market Outlook 2021-2034 by Region
Europe Immuno-oncology Cell Therapy Market Outlook 2021-2034 by Country
North America Immuno-oncology Cell Therapy Market Outlook 2021-2034 by Country
Asia Pacific Immuno-oncology Cell Therapy Market Outlook 2021-2034 by Country
Latin America Immuno-oncology Cell Therapy Market Outlook 2021-2034 by Country
Middle East & Africa Immuno-oncology Cell Therapy Market Outlook 2021-2034 by Country